An AbbVie clinical vet heading early oncology jumps ship to build his own team at NK cell-focused biotech

Making the leap from a mid-sized biotech into the ranks of pharma can be a chafing experience for executives used to a more flexible work environment — and that jump gets even harder during an acquisition. For Thorsten Graef, a clinical veteran who transitioned from Pharmacyclics into AbbVie, the move was a learning experience in terms of what sort of team he wanted to run.